Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an announcement.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has initiated a key late-stage study for its lead asset IMM0306, a bispecific antibody targeting CD47 and CD20 for B-cell malignancies. The company fully owns the global intellectual property and commercial rights to IMM0306, underscoring its strategy to build a proprietary, innovation-driven oncology portfolio.
The company announced that the first patient has been dosed in a Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for relapsed or refractory follicular lymphoma. This milestone advances IMM0306, described as the first CD47/CD20 dual-target bispecific to reach the clinic worldwide, and signals progress toward potential commercialization, though the company cautions there is no guarantee of successful development or marketing.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative immuno-oncology therapies. Its pipeline includes independently developed biologics such as bispecific antibodies targeting immune checkpoints and tumor antigens, with a global market focus supported by ownership of related intellectual property and commercial rights.
Average Trading Volume: 1,694,997
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.64B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.